Dare Bioscience (NASDAQ:DARE) Downgraded to Sell at ValuEngine

ValuEngine cut shares of Dare Bioscience (NASDAQ:DARE) from a hold rating to a sell rating in a report released on Wednesday morning, ValuEngine reports.

Separately, Maxim Group restated a buy rating and issued a $3.00 price objective on shares of Dare Bioscience in a research note on Tuesday, November 12th.

Shares of Dare Bioscience stock traded down $0.07 during trading on Wednesday, hitting $1.62. 47,998 shares of the stock were exchanged, compared to its average volume of 3,394,085. The stock has a market capitalization of $22.86 million, a price-to-earnings ratio of -1.49 and a beta of 1.86. The company has a fifty day moving average price of $0.86 and a 200-day moving average price of $0.82. Dare Bioscience has a 1-year low of $0.69 and a 1-year high of $3.25.

Dare Bioscience (NASDAQ:DARE) last issued its earnings results on Thursday, November 14th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.21) by $0.01. Equities research analysts expect that Dare Bioscience will post -0.99 earnings per share for the current fiscal year.

An institutional investor recently raised its position in Dare Bioscience stock. Susquehanna International Group LLP boosted its stake in shares of Dare Bioscience Inc (NASDAQ:DARE) by 293.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 42,770 shares of the biotechnology company’s stock after purchasing an additional 31,900 shares during the quarter. Susquehanna International Group LLP owned about 0.26% of Dare Bioscience worth $36,000 at the end of the most recent reporting period. 4.82% of the stock is owned by hedge funds and other institutional investors.

Dare Bioscience Company Profile

Daré Bioscience, Inc, a clinical-stage biopharmaceutical company, focuses on developing and marketing women's reproductive health products in the United States. The company intends to develop therapies in the areas of contraception, vaginal health, sexual health, and fertility. Its product candidates include Ovaprene, a non-hormonal monthly contraceptive; and SST-6007, a topical sildenafil cream for female sexual arousal disorder.

Featured Article: How can investors find ex-dividend dates?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Dare Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dare Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.